pazopanib hydrochloride
pazopanib hydrochloride is listed in the FDA National Drug Code directory with 5 NDC codes, marketed under brand names including VOTRIENT, pazopanib. Available dosage form: tablet, film coated.
Drug Details
- Generic Name
- pazopanib hydrochloride
- Brand Names
- VOTRIENT, pazopanib
- Application Number
- NDA022465
- Sponsor
- Novartis Pharmaceuticals Corporation
- NDC Codes
- 5
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- PAZOPANIB HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE VOTRIENT is a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). ( 1.1 ) advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use : The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. 1.1 Renal Cell Carcinoma VOTRIENT ® is indicated for the treatment of adults with advanced renal cell carcinoma (RCC). 1.2 Soft Tissue Sarcoma VOTRIENT is indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use : The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.